Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 107-116

  Ye, Weiping ^a   Chang, Hsiang Lin ^a   Wang, Li Shu ^a   Huang, Yi Wen ^a   Shu, Sherry ^a   Dowd, Michael K ^c   Wan, Peter J ^c   Sugimoto, Yasuro ^a,b   Lin, Young C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

Author keywords

Breast cancer; MDR1; Multidrug resistance; P glycoprotein

Indexed keywords

COTTON SEED OIL; DOXORUBICIN; FULVESTRANT; GLYCOPROTEIN P; GOSSYPOL; MULTIDRUG RESISTANCE PROTEIN 1; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; MODULATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; COTTONSEED OIL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; GENE EXPRESSION; GENES, MDR; GOSSYPOL; HUMANS; P-GLYCOPROTEIN; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 33847650043     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murry T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Smigal C, Jemal A, Ward E, Collinides V and Smith R: Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56: 168-183, 2006.
3. Litman T, Druly TE, Stein WD and Bates SE: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. 58: 931-959, 2001.
4. Gottesman MM and Ambudkar SV: NiB. Exploiting multidrug resistance to treat cancer. Cold Spring Harbor Symp Quant Biol 59: 677-683, 1994.
5. Juliano RL and Ling VA: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152-162, 1976.
6. Pérez-Tomás R: Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Current Medicinal Chemistry 13: 1859-1876, 2006.
7. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485, 2003.
8. Golstein D and Laszlo J: Interferon therapy in cancer: from imaginon to interferon. Cancer Res 46: 4315-4329, 1986.
9. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R and Chassagne J: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Nat Cancer Inst 83(2): 111-116, 1991.
10. Walker J, Martin C and Callaghan R: Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40(4): 594-605, 2004.
11. Adams R, Geissman TA and Edwards JD: Gossypol, a pigment of cottonseed. Chem Rev 60: 555-574, 1960.
12. Anonymous. Gossypol - a new anti-fertility agent for males. Gyn Obstet Invest 10(4): 163-176, 1979.
13. Tuszynski GP and Cossu G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res 44(2): 768-771, 1984.
14. Hu YF, Chang CJ, Brueggemeier RW and Lin YC: Gossypol inhibits basal and estrogen-stimulated DNA synthesis in human breast carcinoma cells. Life Sci 53(25): PL 433-438, 1993.
15. Dao VT, Dowd MK, Martin MT, Gaspard C, Mayer M and Michelot RJ: Cytotoxicity of enantiomers of gossypol Schiffs bases and optical stability of gossypolone. Eur J Med Chem 39(7): 619-624, 2004.
16. Joseph AE, Matlin SA and Knox P: Cytotoxicity of enantiomers of gossypol. Brit J Cancer 54(3): 511-513, 1986.
17. Zhang Y, Sugimoto Y, Kulp SK, Brueggemeier RW and Lin YC: The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor b1 production. Int J Oncol 13: 1291-1297, 1998.
18. Liu S, Kulp SK, Sugimoto Y, Jiang J, Chang HL, Dowd MK and Lin YC: The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res 22: 33-38, 2002.
19. Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58: 137-171, 1989.
20. Moscow JA and Cowan KH: Multidrug resistance. Cancer Chemother Biol Resp Mod 11: 97-114, 1990.
21. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and Wolmark N: Tam for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Nat Cancer Inst 90(18): 1371-1388, 1998.
22. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J and Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tam randomised chemoprevention trial. Lancet 352(9122): 98-101, 1998.
23. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N and Boyle P: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352(9122): 93-97, 1998.
24. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M and Gustafsson JA: Estrogen receptor beta in breast cancer. Endocrine-Related Cancer 9(1): 1-13, 2002.
25. Hirokawa Y, Arnold M, Nakajima, H, Zalcberg J and Manila H: Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen - resistance. Cancer Biology & Therapy 4(9): 956-960, 2005.
26. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of Tam resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Nat Cancer Inst 96(12): 926-935, 2004.
27. Johnston S: Molecular insights into endocrine resistance. EJC Supplements 3(3): 225-236. 2005
28. Lykkesfeldt AE: Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 35 Suppl 5: 9-14, 1996.
29. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 11: 643-658, 2004.
30. Venditti M, Iwasiow B, Orr FW and Shiu RPC: C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 99(1): 35-42, 2002.
31. Yutaka O, Katsuki S, Keisuke A, Akio H, Shinji U, Takeshi H, Kazumi K, Hisashi S, Kazuhiko Y, Noriko U, Masao K and Tadashi K: Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer. Breast cancer (Tokyo, Japan) 11(3): 309-312, 2004.
32. Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M, Uzan S, Lotz JP, Touboul E and Lacave R: Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. British Journal of Cancer 94(4): 473-480, 2006.
33. Saeki T, Tsuruo T, Sato W and Nishikawsa K: Drug resistance in chemotherapy for breast cancer. Cancer Chemotherapy and Pharmacology 56(Suppl. 1): s84-s89, 2005.
34. Wang CS, LaRue H, Fortin A, Gariepy G and Tetu B: MDR1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res Treat 45(1): 63-74, 1997.
35. Trock BJ, Leonessa F and Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Nat Cancer Inst 89(13): 917-931, 1997.
36. Walker J, Martin C and Callaghan R: Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40(4): 594-605, 2004.
37. Ries LAG: United States. Dept. of Health and Human Services and National Cancer Institute (US). Division of Cancer Control and Population Sciences. Surveillance Research Program., SEER cancer statistics review, 1973-1997. US Dept. of Health and Human Services Public Health Service National Institutes of Health National Cancer Institute, Bethesda, MD, USA, 2000.
38. Ferton JI and Hord NG: Stage matters: choosing relevant model systems to address hypotheses in diet and cancer chemoprevention research. Carcinogenesis 27(5): 893-902, 2006.
39. Jaroszewski JW, Kaplan O and Cohen JS: Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies. Cancer Res 50(21): 6936-6943, 1990.
40. Hu YF, Chang CJG, Brueggemeier RW and Lin YC: Presence of antitumor activities in the milk collected from gossypol-treated dairy cows. Cancer Lett 7: 17-23, 1994.